PMID: 9420292Jan 7, 1998Paper

Minimal requirement for a lentivirus vector based on human immunodeficiency virus type 1

Journal of Virology
V N KimA J Kingsman

Abstract

The use of human immunodeficiency virus vectors for gene therapy is hampered by concern over their safety. This concern might be ameliorated, in part, if the viral accessory genes and proteins could be eliminated from the vector genomes and particles. Here we describe a minimal vector system that is capable of transducing nondividing cells and which does not contain tat, vif, vpr, vpu, and nef.

References

Sep 1, 1992·Virology·L Fan, K Peden
May 11, 1992·Journal of Virology·G L Buchschacher, A T Panganiban
Jul 15, 1992·Proceedings of the National Academy of Sciences of the United States of America·M I BukrinskyM Stevenson
Jul 1, 1989·Proceedings of the National Academy of Sciences of the United States of America·E F TerwilligerW A Haseltine
May 23, 1995·Proceedings of the National Academy of Sciences of the United States of America·A AlbiniB Ensoli
Aug 1, 1995·Journal of Virology·C Aiken, D Trono
Mar 1, 1995·The Journal of General Virology·J H RichardsonA M Lever
Nov 1, 1994·Journal of Virology·R A Subbramanian, E A Cohen
Jul 19, 1994·Proceedings of the National Academy of Sciences of the United States of America·U von SchwedlerD Trono
Jul 19, 1994·Proceedings of the National Academy of Sciences of the United States of America·N K HeinzingerM Emerman
Feb 15, 1994·Proceedings of the National Academy of Sciences of the United States of America·M BrayM L Hammarskjöld
Jul 1, 1996·Journal of Virology·H YuJ P Dougherty
Oct 15, 1996·Proceedings of the National Academy of Sciences of the United States of America·L NaldiniI M Verma
Oct 15, 1996·Proceedings of the National Academy of Sciences of the United States of America·E PoeschlaF Wong-Staal
Sep 10, 1996·Human Gene Therapy·G RossB R Smith

❮ Previous
Next ❯

Citations

Dec 4, 1998·Springer Seminars in Immunopathology·P D RobbinsY Chernajovsky
Feb 12, 1999·Arteriosclerosis, Thrombosis, and Vascular Biology·I J KulloR S Schwartz
Oct 24, 2000·Journal of Virology·J ReiserR O Brady
Dec 19, 2001·Human Gene Therapy·M Fuller, D S Anson
Oct 25, 2002·AIDS Research and Human Retroviruses·Chen LiangMark A Wainberg
Apr 20, 2005·Birth Defects Research. Part C, Embryo Today : Reviews·Naoya KobayashiNoriaki Tanaka
Nov 17, 2007·Molecules : a Journal of Synthetic Chemistry and Natural Product Chemistry·H EliyahuA J Domb
Sep 18, 2007·Molecular Biotechnology·Adam S Cockrell, Tal Kafri
Jan 25, 2020·Viruses·Maria C Virgilio, Kathleen L Collins
Nov 25, 2000·Journal of Hematotherapy & Stem Cell Research·Y HanazonoC E Dunbar
Feb 8, 2003·DNA and Cell Biology·Ricardo Quinonez, Richard E Sutton
Feb 13, 2002·AIDS Patient Care and STDs·Mario R Mautino, Richard A Morgan
May 12, 2005·Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft·S C BeutelspacherM O McClure
Feb 12, 2008·Current Protocols in Molecular Biology·Ali Ramezani, Robert G Hawley
Dec 9, 2016·Journal of Occupational and Environmental Medicine·Ryan SchlimgenJatin M Vyas
Dec 20, 2005·The Journal of Pathology·Lawrence S YoungVivien Mautner
Jan 18, 2006·Human Gene Therapy·Liang-Fong WongNicholas D Mazarakis
Aug 5, 2003·The Journal of Gene Medicine·Karine BreckpotKris Thielemans
May 18, 2007·Journal of Biomolecular Screening·Nicholas A GrahamAnand R Asthagiri
Mar 7, 2020·BioTechniques·Sunhye Lee, David Cobrinik

❮ Previous
Next ❯

Related Concepts

Related Feeds

CREs: Gene & Cell Therapy

Gene and cell therapy advances have shown promising outcomes for several diseases. The role of cis-regulatory elements (CREs) is crucial in the design of gene therapy vectors. Here is the latest research on CREs in gene and cell therapy.